Osteoporosis is a skeletal condition in which bones lose density and their internal architecture deteriorates, making them fragile enough to fracture from forces that healthy bone would easily withstand. Roughly one in three women and one in five men over the age of 50 will experience an osteoporotic fracture in their remaining lifetime, yet most people with the condition have no symptoms at all until a bone breaks. The biology behind it centers on a slow-motion imbalance between the cells that build bone and the cells that tear it down, and the tipping point is driven by a mix of hormones, genetics, medications, and daily habits that are worth understanding in detail.
How Bone Stays Healthy and How the Balance Tips
Bone is not a static scaffold. Your skeleton constantly remodels itself: specialized cells called osteoclasts dissolve old or damaged bone, and osteoblasts lay down fresh tissue in its place. In a young, healthy adult these two processes stay roughly in equilibrium, so the total amount of bone holds steady. Osteoporosis develops when resorption outpaces formation for long enough that the skeleton becomes structurally compromised.
The most common trigger for that imbalance is estrogen loss after menopause. Estrogen keeps osteoclast activity in check, partly by suppressing a signaling molecule called RANKL in bone lining cells. Mouse studies have shown that removing ovaries leads to roughly a threefold increase in RANKL expression in those cells, and replacing estrogen brings it back to normal levels.1PubMed Central. Estrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells Separate experiments deleting the RANKL gene specifically in osteocytes, the long-lived cells embedded deep inside bone, have confirmed that osteocyte-produced RANKL is essential for the bone loss that follows estrogen withdrawal.2Journal of Biological Chemistry. Deletion of Tnfsf11 from osteocytes prevents estrogen deficiency-induced bone loss and increases in bone marrow B cells in mice In practical terms, when estrogen drops, the brake on bone-dissolving cells lifts, and the skeleton starts losing material faster than it can rebuild.
Diagnosis Before the First Fracture
Because osteoporosis is painless until something breaks, screening matters. The standard diagnostic tool is a dual-energy X-ray absorptiometry scan, commonly called a DXA scan. It measures bone mineral density at the hip and spine and converts the result into a T-score, which compares your density to the average value for a healthy young adult. A T-score of –2.5 or lower means osteoporosis; between –1.0 and –2.5 is classified as osteopenia, a milder thinning that still raises fracture risk above normal.3PubMed. Use of dual-energy X-ray absorptiometry (DXA) for diagnosis and fracture risk assessment; WHO-criteria, T- and Z-score, and reference databases
A DXA scan tells you how much mineral is packed into bone, but it does not capture everything about bone quality. That is where trabecular bone score, or TBS, adds value. TBS is a texture measurement derived from the same DXA image, and a low TBS indicates degraded microarchitecture that predicts fracture risk partly independent of density.4PubMed Central. Update on trabecular bone score Large international cohort data confirm that deficits in both trabecular and cortical bone structure contribute to fracture risk independently.5The Lancet Diabetes & Endocrinology. Association of bone microarchitecture and stiffness with fracture risk In other words, two people can have the same T-score but very different fracture odds because one has more disorganized internal bone structure.
Clinicians also use a web-based calculator called FRAX, which estimates your ten-year probability of a major osteoporotic fracture or hip fracture based on age, sex, weight, smoking status, alcohol use, steroid use, and other clinical factors. It can be run with or without a DXA result, which makes it useful as a first-line screening step in settings where DXA is not readily available.6PubMed Central. An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis FRAX is not perfect: a Spanish validation study found its sensitivity for predicting major fractures was below fifty percent, meaning it misses a substantial share of people who do go on to fracture.7PubMed Central. FRAX tool, the WHO algorithm to predict osteoporotic fractures: the first analysis of its discriminative and predictive ability in the Spanish FRIDEX cohort Still, it is a useful triage tool, especially for deciding who should get further testing.
What Makes Some People More Vulnerable
The biggest non-modifiable risk factor is genetics. A genome-wide polygenic study of postmenopausal women found a fivefold gradient in the risk of major osteoporotic fracture across genetic risk categories, with those in the highest-risk tenth of the genetic spectrum facing roughly three and a half times the fracture risk for any fracture compared to the rest of the population.8PubMed Central. Genome-wide polygenic risk score for major osteoporotic fractures in postmenopausal women using associated single nucleotide polymorphisms If your mother or father had a fragility fracture, particularly a hip fracture, your own risk is elevated regardless of what your DXA shows.
Beyond genetics, several modifiable and semi-modifiable factors stack the odds:
- Age and sex: Women lose bone rapidly in the five to seven years after menopause. Men lose bone more gradually but catch up in their seventies and eighties.
- Body weight: Very low body weight correlates with lower bone density. Mechanical loading from body mass itself provides a stimulus that helps maintain bone.
- Smoking and alcohol: Both impair osteoblast function. Heavy alcohol intake also increases fall risk.
- Chronic diseases: Conditions that alter hormone balance, gut absorption, or inflammation, including celiac disease, rheumatoid arthritis, type 1 diabetes, and hyperthyroidism, can accelerate bone loss.
When Medications Cause Bone Loss
Glucocorticoids (drugs like prednisone and dexamethasone) are the most common medication-driven cause of osteoporosis. They work against bone on multiple fronts: they directly suppress the bone-building activity of osteoblasts, they ramp up osteoclast formation early in treatment, they antagonize sex hormones, and they impair calcium absorption in the gut while increasing calcium loss through the kidneys.9PubMed. Mechanisms of glucocorticoid-induced osteoporosis 10Bone. Molecular mechanisms of glucocorticoid-induced osteoporosis The result is that fracture risk rises quickly after starting steroids, sometimes within the first few months, even before bone density has dropped much. This is partly because glucocorticoids also impair the repair of microscopic damage inside bone, so the skeleton weakens in ways a DXA scan does not fully capture.11The Lancet Diabetes & Endocrinology. Glucocorticoid-induced osteoporosis: pathophysiology, prevention, and treatment
Other medications linked to bone loss include certain anti-seizure drugs, proton-pump inhibitors used long-term for acid reflux, and hormone-deprivation therapies used in breast and prostate cancer treatment. Anyone on long-term glucocorticoids should discuss bone-protective strategies with their physician early rather than waiting for a fracture to prompt the conversation.
Why Hip Fractures Are So Dangerous
The most feared consequence of osteoporosis is a hip fracture. It is not just a broken bone: it is a health crisis, especially for older adults. A Canadian study found that about a quarter of patients who fracture a hip die within one year, and among those who were living in institutions before the fracture, mortality reached nearly forty percent.12Journal SOGC. Mortality, Independence in Living, and Re-fracture, One Year Following Hip Fracture in Canadians A Hong Kong follow-up study reported cumulative mortality reaching about a third by three years.13PubMed Central. Factors Affecting Mortality and Hospital Admissions after Hip Surgery among Elderly Patients with Hip Fracture in Hong Kong – Review of a Three-Year Follow-Up
For survivors, the disability burden is severe. A critical review found that between forty and sixty percent of hip fracture survivors recover their pre-fracture mobility, while among those who were previously independent in self-care, twenty to sixty percent still need help with daily tasks one to two years after the break.14PubMed Central. A critical review of the long-term disability outcomes following hip fracture Many formerly independent people end up in long-term care. This is the real reason osteoporosis screening matters: it is not about bone density numbers on a report, it is about preventing a cascade of lost independence.
Exercise as a Bone-Building Tool
To trigger bone growth, the skeleton needs to experience forces that exceed what it handles during everyday walking and sitting. Resistance training is one of the best-studied approaches for preserving both bone and muscle mass in people at risk.15PubMed Central. Effects of Resistance Exercise on Bone Health A network meta-analysis of exercise types in postmenopausal women found that combining aerobic exercise with resistance training produced the largest improvements in bone density at both the lumbar spine and the femoral neck, followed by aerobic exercise alone and resistance training alone.16Scientific Reports. Effect of different types of exercise on bone mineral density in postmenopausal women: a systematic review and network meta-analysis
Intensity matters. The LIFTMOR trial enrolled postmenopausal women with osteopenia or osteoporosis and put them through a high-intensity resistance and impact training program. After eight months, the exercise group gained about three percent in lumbar spine density while the control group lost roughly one percent. Femoral neck density, height, and functional performance all improved in the exercise group as well, and no adverse events occurred under supervised conditions.17Journal of Bone and Mineral Research. High‐Intensity Resistance and Impact Training Improves Bone Mineral Density and Physical Function in Postmenopausal Women With Osteopenia and Osteoporosis: The LIFTMOR Randomized Controlled Trial That last point is worth underlining: the longstanding clinical caution that people with fragile bones should avoid heavy lifting may be overly conservative when the training is properly supervised.
Calcium, Vitamin D, and the Supplement Question
Calcium and vitamin D are the baseline nutritional building blocks for bone, but the evidence on whether supplementing them actually prevents fractures is more nuanced than the “take your calcium” messaging suggests. A large meta-analysis found that vitamin D supplements alone, without added calcium, did not reduce fracture risk at all.18PubMed Central. Vitamin D and Calcium for the Prevention of Fracture: A Systematic Review and Meta-analysis Combined supplementation with vitamin D and calcium fared better, showing about a six percent reduction in any fracture and a sixteen percent reduction in hip fracture across six large trials.19PubMed Central. Vitamin D and Calcium for the Prevention of Fracture: A Systematic Review and Meta-analysis
Dose and frequency seem to matter. A separate meta-analysis found that daily vitamin D in the range of 800 to 1,000 IU was associated with lower fracture and fall risk, while doses below or above that range were not, and intermittent large bolus doses were not effective for reducing falls.20PubMed Central. Effect of Vitamin D Supplementation on Risk of Fractures and Falls According to Dosage and Interval: A Meta-Analysis One caveat from the Women’s Health Initiative trial: calcium plus vitamin D supplementation slightly increased the risk of kidney stones.21PubMed. Calcium plus vitamin D supplementation and the risk of fractures The practical takeaway is that getting enough calcium from food (dairy, leafy greens, fortified products) and maintaining adequate vitamin D through moderate sun exposure or a modest daily supplement is a reasonable baseline, but supplements are not a magic shield against fractures.
Drug Treatment and Sequencing Strategy
When lifestyle measures are not enough, there are two broad classes of osteoporosis drugs: antiresorptives, which slow the breakdown of bone, and anabolic agents, which stimulate new bone formation.
Bisphosphonates (alendronate, risedronate, zoledronic acid) are the most widely prescribed antiresorptives. They work by poisoning osteoclasts, effectively putting a brake on bone resorption. They are effective and generally safe over a course of three to five years, but long-term use carries a paradox: by suppressing the normal bone-remodeling cycle too completely, they allow microcracks to accumulate, which can actually weaken bone over time.22Scientific Reports. Long-term effects of bisphosphonate therapy: perforations, microcracks and mechanical properties This is why doctors often recommend a “drug holiday” after several years, though the timing and safety of doing so remain debated.
Denosumab is another antiresorptive, an injected antibody given every six months. It effectively increases bone density and reduces fractures for as long as you take it, but stopping is risky. Discontinuation triggers a rebound surge in osteoclast activity that can cause rapid, profound bone loss and, in some patients, multiple vertebral fractures.23PubMed Central. Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review 24PubMed Central. Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature If denosumab needs to be stopped, the standard approach is to transition to a bisphosphonate to prevent the rebound.
For patients at high fracture risk, anabolic agents offer a different approach. Teriparatide and abaloparatide mimic parathyroid hormone and stimulate osteoblasts to build new bone. Romosozumab is a newer antibody that blocks sclerostin, a protein that normally inhibits bone formation; it has the unusual property of both increasing formation and decreasing resorption simultaneously.25PubMed Central. Profile of romosozumab and its potential in the management of osteoporosis 26PubMed. Romosozumab Treatment in Postmenopausal Women with Osteoporosis A real-world study comparing romosozumab to teriparatide found that romosozumab produced roughly double the lumbar spine density gain over its treatment course.27PubMed. A new age of osteoanabolic therapy? A real-world, two-centre study comparing effects of romosozumab, teriparatide, and antiresorptive therapies for osteoporosis
A critical insight from recent trial data is that the order of treatment matters. Starting with an anabolic agent and then switching to an antiresorptive drug produces better bone density gains and faster fracture reduction than the reverse sequence.28Endocrine Practice. Anabolic Therapy and Optimal Treatment Sequences for Patients With Osteoporosis at High Risk for Fracture 29PubMed Central. Anabolic therapy for osteoporosis: update on efficacy and safety Despite this evidence, many patients are still started on bisphosphonates first simply because they are cheaper and more familiar, which may not be ideal for someone at very high risk.
Why So Many People Stop Treatment
Osteoporosis medications have an adherence problem that is worse than many chronic diseases. A study examining why patients declined prescribed osteoporosis treatment found that the most common reason, cited by over half, was fear of side effects. About a quarter said they simply disliked taking medication, and roughly one in six believed the drug would not help them.30Journal of the American Pharmacists Association. Patient-activation and guideline-concordant pharmacological treatment after bone density testing: the PAADRN randomized controlled trial Those concerns are understandable: rare but alarming side effects like jawbone damage and atypical femur fractures have received extensive media coverage, and because osteoporosis itself has no day-to-day symptoms, it is hard to feel motivated to take a pill for something you cannot feel. Studies confirm that safety worries and lack of motivation are the most consistent predictors of discontinuation across drug classes.31PubMed. Determinants of adherence to osteoporosis treatment in clinical practice
One systems-level response to the adherence and care gap has been the creation of fracture liaison services. These are hospital-based programs that identify patients who have already sustained a fragility fracture and systematically connect them with screening, treatment, and follow-up. The logic is straightforward: someone who has already broken a bone is at high risk for another one, and the moment of fracture is the best opportunity to intervene. Evidence shows these services improve rates of treatment initiation and persistence on medication.32PubMed. Effectiveness of fracture liaison services in osteoporosis 33PubMed Central. Efficacy and efficiency of fracture liaison services to reduce the risk of recurrent osteoporotic fractures
Men and the Screening Gap
Osteoporosis is often framed as a women’s disease, and that framing has real consequences. Men account for a substantial share of osteoporotic fractures, particularly hip fractures, and their outcomes after a hip fracture tend to be worse than women’s. Yet the literature consistently shows that male osteoporosis is underscreened, underdiagnosed, and undertreated, both in primary and secondary prevention of fractures.34PubMed Central. Osteoporosis in Men: A Review of an Underestimated Bone Condition Most screening guidelines focus on postmenopausal women or set the age threshold for men at 70, meaning many men with significant risk factors such as glucocorticoid use, low testosterone, or heavy alcohol intake are never tested.
When Bone Loss Meets Muscle Loss
Osteoporosis rarely travels alone in older adults. Sarcopenia, the age-related loss of muscle mass and strength, shares many of the same drivers: hormonal decline, physical inactivity, poor nutrition, and chronic inflammation. When both conditions occur together, the combination is sometimes called osteosarcopenia, and it creates a vicious loop: weak muscles increase fall risk, and fragile bones make every fall more likely to end in a fracture.35PubMed. Sarcopenia, osteoporosis and frailty 36PubMed. Osteosarcopenia: beyond age-related muscle and bone loss This overlap is one reason resistance exercise gets so much emphasis in prevention: it is one of the few interventions that addresses both bone density and muscle strength at the same time.
The Gut Microbiome Connection
An area of active research that may reshape thinking about osteoporosis in the coming years is the gut microbiome. Animal and early human studies suggest that gut bacteria influence bone metabolism through several pathways: they help produce short-chain fatty acids that affect mineral absorption, they modulate immune cells that regulate osteoclast activity, and they may influence bone through the gut-brain axis by affecting serotonin signaling.37PubMed Central. Gut Microbiome and Osteoporosis Some experimental interventions using probiotics have shown small positive effects on bone density markers in animal models. Whether this translates into a meaningful fracture-prevention strategy in humans is still unclear, but it represents a genuinely novel angle on a condition that has been managed primarily through hormones, minerals, and pharmaceuticals for decades.